๐Ÿ—‚ ็ธฝ็›ฎ้Œ„ ๏ฝœ ๐Ÿ“– ่‹ฑๆ–‡ๅŽŸๆ–‡๏ผˆๆœฌ็ฏ‡๏ผ‰ ๏ฝœ ๐Ÿ“ ๅฎŒๆ•ด็ฟป่ญฏ ๏ฝœ โญ ็ฒพ่ฏ็ญ†่จ˜

BACKGROUND

BACKGROUND

William Norris, a Scottish surgeon, reported the first case of cutaneous melanoma in
1820. He also observed high numbers of nevi on his patient, and proposed that the two conditions may be related.5 In the 1970s, CAN/DN were described among individuals from melanoma-prone families. In 1978, Clark and colleagues described CAN/DN as part of the โ€œB-K mole syndromeโ€ (named for two patients in the study) among patients from families affected by familial malignant melanoma (FMM).6 Around the same time, Lynchโ€™s group described four individuals in a melanoma-prone family, and found three of them to have a larger number of CAN (>200).7 In 1980, Elder et al. proposed the term โ€œdysplastic nevusโ€ for these morphologically atypical moles with irregular outlines and pigmentation that tended to occur more commonly on sun-protected areas when compared with common or banal nevi (CN) and had histologic evidence of dysplasia.8 The National Institutes of Health (NIH) held a consensus meeting to further define the histologic criteria for DN in 1992 and recommended the clinical term โ€œatypical nevusโ€ versus the pathologic term, โ€œnevus with architectural disorder.โ€9